BR112019003131A2 - processo para preparar micropartículas contendo acetato de glatirâmero - Google Patents

processo para preparar micropartículas contendo acetato de glatirâmero

Info

Publication number
BR112019003131A2
BR112019003131A2 BR112019003131-6A BR112019003131A BR112019003131A2 BR 112019003131 A2 BR112019003131 A2 BR 112019003131A2 BR 112019003131 A BR112019003131 A BR 112019003131A BR 112019003131 A2 BR112019003131 A2 BR 112019003131A2
Authority
BR
Brazil
Prior art keywords
glatiramer acetate
microparticles containing
preparing microparticles
containing glatiramer
microparticles
Prior art date
Application number
BR112019003131-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Bleich Kimelman Nadav
Rubnov Shai
Marom Ehud
Original Assignee
Mapi Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd. filed Critical Mapi Pharma Ltd.
Publication of BR112019003131A2 publication Critical patent/BR112019003131A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/36Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino acids, polyamines and polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
BR112019003131-6A 2016-08-28 2017-08-28 processo para preparar micropartículas contendo acetato de glatirâmero BR112019003131A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380426P 2016-08-28 2016-08-28
US62/380,426 2016-08-28
PCT/IL2017/050954 WO2018042423A1 (en) 2016-08-28 2017-08-28 Process for preparing microparticles containing glatiramer acetate

Publications (1)

Publication Number Publication Date
BR112019003131A2 true BR112019003131A2 (pt) 2019-05-21

Family

ID=61301634

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003131-6A BR112019003131A2 (pt) 2016-08-28 2017-08-28 processo para preparar micropartículas contendo acetato de glatirâmero

Country Status (11)

Country Link
US (1) US11471421B2 (enExample)
EP (1) EP3503907B1 (enExample)
JP (2) JP7232752B2 (enExample)
CN (1) CN109689082A (enExample)
AU (1) AU2017319781B2 (enExample)
BR (1) BR112019003131A2 (enExample)
CA (1) CA3035149A1 (enExample)
ES (1) ES2979169T3 (enExample)
IL (1) IL264824B (enExample)
MX (1) MX2019001999A (enExample)
WO (1) WO2018042423A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
AU2018242998B2 (en) * 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN111249524B (zh) * 2020-01-18 2020-12-08 南京医科大学附属口腔医院 用于骨组织再生的高孔隙率聚己内酯多孔微球支架及其制备方法
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CN1398584A (zh) 2002-07-15 2003-02-26 裴福兴 一种bFGF-PLGA缓释微球及其制备方法和用途
EP1648398A2 (en) 2003-07-31 2006-04-26 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP3536333B1 (en) 2010-01-04 2022-08-03 Mapi Pharma Limited Depot system comprising glatiramer acetate
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
CN103169670B (zh) * 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Also Published As

Publication number Publication date
JP7232752B2 (ja) 2023-03-03
EP3503907A1 (en) 2019-07-03
US20210299057A1 (en) 2021-09-30
AU2017319781A1 (en) 2019-02-07
IL264824B (en) 2022-03-01
JP2023022199A (ja) 2023-02-14
EP3503907B1 (en) 2024-03-13
JP2019537551A (ja) 2019-12-26
EP3503907A4 (en) 2020-05-20
ES2979169T3 (es) 2024-09-24
EP3503907C0 (en) 2024-03-13
CA3035149A1 (en) 2018-03-08
AU2017319781B2 (en) 2021-05-27
CN109689082A (zh) 2019-04-26
US11471421B2 (en) 2022-10-18
WO2018042423A1 (en) 2018-03-08
MX2019001999A (es) 2019-08-29

Similar Documents

Publication Publication Date Title
BR112019003131A2 (pt) processo para preparar micropartículas contendo acetato de glatirâmero
CL2019001365A1 (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y aditivo que contiene el polipéptido, uso y procedimiento de los mismos. (divisional solicitud 201600464)
MX395007B (es) Inhibidores de tirosina-cinasas
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112016006182A8 (pt) composição veterinária de longa duração, uso de uma isoxazolina espirocíclica para preparação da mesma, bem como processo para a preparação de uma microesfera
MX2017006942A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
BR112019007309A2 (pt) anticorpos anti-c1s e métodos de uso dos mesmos
UY36589A (es) Compuestos químicos
BR112014012789A2 (pt) agentes terapêuticos compreendendo sequências de aminoácidos de insulina
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
EA201790721A1 (ru) Инъекционный состав бупренорфина
MX382161B (es) Una composicion plastificante que comprende di (2-etilhexil) tereftalato.
MX2019012452A (es) Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
NZ710602A (en) Methods for reducing pyrogenicity in a seaweed extract
DOP2019000047A (es) Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres
CO2017001454A2 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.
MX2016014826A (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
BR112012022946A2 (pt) método para proliferar cardiomiócitos usando micro-rna
BR112018077397A2 (pt) diprovocims: uma classe de agonistas de tlr
MY185942A (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
AR099070A1 (es) Ácido (s)- 3-metil-abscísico y ésteres del mismo
BR112015016780A2 (pt) Peptídios
AR099563A1 (es) PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]